These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22579442)

  • 1. Microbial contamination of non-invasive ventilation devices used by adults with cystic fibrosis.
    Mutagi A; Nash EF; Cameron S; Abbott G; Agostini P; Whitehouse JL; Honeybourne D; Boxall E
    J Hosp Infect; 2012 Jun; 81(2):104-8. PubMed ID: 22579442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.
    Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M
    J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology.
    Mahenthiralingam E; Baldwin A; Dowson CG
    J Appl Microbiol; 2008 Jun; 104(6):1539-51. PubMed ID: 18217926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre.
    Dobbin C; Maley M; Harkness J; Benn R; Malouf M; Glanville A; Bye P
    J Hosp Infect; 2004 Apr; 56(4):277-82. PubMed ID: 15066737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults.
    Courtney JM; Dunbar KE; McDowell A; Moore JE; Warke TJ; Stevenson M; Elborn JS
    J Cyst Fibros; 2004 Jun; 3(2):93-8. PubMed ID: 15463892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward.
    Döring G; Jansen S; Noll H; Grupp H; Frank F; Botzenhart K; Magdorf K; Wahn U
    Pediatr Pulmonol; 1996 Feb; 21(2):90-100. PubMed ID: 8882212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
    Elborn JS; Hodson M; Bertram C
    J Cyst Fibros; 2009 May; 8(3):211-7. PubMed ID: 19372063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.
    Jones AM; Dodd ME; Govan JR; Barcus V; Doherty CJ; Morris J; Webb AK
    Thorax; 2004 Nov; 59(11):948-51. PubMed ID: 15516469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria.
    Hadjiliadis D; Steele MP; Chaparro C; Singer LG; Waddell TK; Hutcheon MA; Davis RD; Tullis DE; Palmer SM; Keshavjee S
    J Heart Lung Transplant; 2007 Aug; 26(8):834-8. PubMed ID: 17692788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic fibrosis infections: treatment strategies and prospects.
    George AM; Jones PM; Middleton PG
    FEMS Microbiol Lett; 2009 Nov; 300(2):153-64. PubMed ID: 19674113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burkholderia cepacia complex in cystic fibrosis and non-cystic fibrosis patients: identification of a cluster of epidemic lineages.
    Agodi A; Barchitta M; Gianninò V; Collura A; Pensabene T; Garlaschi ML; Pasquarella C; Luzzaro F; Sinatra F; Mahenthiralingam E; Stefani S
    J Hosp Infect; 2002 Mar; 50(3):188-95. PubMed ID: 11886194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of mortality in adults with cystic fibrosis.
    Courtney JM; Bradley J; Mccaughan J; O'Connor TM; Shortt C; Bredin CP; Bradbury I; Elborn JS
    Pediatr Pulmonol; 2007 Jun; 42(6):525-32. PubMed ID: 17469153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting.
    O'Malley CA; VandenBranden SL; Zheng XT; Polito AM; McColley SA
    Respir Care; 2007 Mar; 52(3):258-62. PubMed ID: 17328823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
    Savoia D; Deplano C; Zucca M
    Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation?
    Olland A; Falcoz PE; Kessler R; Massard G
    Interact Cardiovasc Thorac Surg; 2011 Dec; 13(6):631-4. PubMed ID: 21920934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.
    Holby N; Olling S
    Acta Pathol Microbiol Scand C; 1977 Apr; 85(2):107-14. PubMed ID: 404841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion.
    Lynch JP
    Semin Respir Crit Care Med; 2009 Oct; 30(5):596-610. PubMed ID: 19760547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection control and the significance of sputum and other respiratory secretions from adult patients with cystic fibrosis.
    Moore JE; Shaw A; Howard JL; Dooley JS; Elborn JS
    Ann Clin Microbiol Antimicrob; 2004 Jun; 3():8. PubMed ID: 15175107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P; Widmer F; Middleton PG; Iredell J; George AM
    FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low level of bacterial contamination of mist tents used in home treatment of cystic fibrosis patients.
    Jakobsson B; Hjelte L; Nyström B
    J Hosp Infect; 2000 Jan; 44(1):37-41. PubMed ID: 10633052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.